Brought to you by 
Tesaro grants Jiangsu Hengrui exclusive license to rolapitant in China
01 Feb 2023
Executive Summary
Tesaro Inc. licensed Jiangsu Hengrui Medicine Co. Ltd. exclusive rights to develop, register, manufacture, and commercialize rolapitant in China.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Tesaro grants Jiangsu Hengrui exclusive license to rolapitant in China
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice